Aligos Therapeutics, Inc. (ALGS) vs Accuray Incorporated (ARAY)

A side-by-side comparison of Aligos Therapeutics, Inc. and Accuray Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ALGS vs ARAY

growth of $100 · dividends reinvested · last 6y
ALGS -98.5% (-50.6%/yr)ARAY -89.7% (-31.5%/yr)ARAY compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $100202120222023202420252026$1$10
ALGS ARAY

ALGS vs ARAY: by the numbers

  • •ARAY is the larger company ($37M vs $33M market cap).
  • •Both run net losses; ARAY's is the smaller (-12.24% vs -241.01% net margin).
  • •ARAY grew revenue faster over the past five years (0.28% vs -15.85% CAGR).

Metrics side by side

Valuation

MetricALGSARAY
P/S ratio1.030.09
P/B ratio1.020.88

Profitability

MetricALGSARAY
Gross margin57.46%27.73%
Operating margin-4024.93%-6.58%
Net margin-241.01%-12.24%
ROE-238.24%-117.97%
ROIC-207.97%-10.09%

Growth (annualized)

MetricALGSARAY
Revenue CAGR (5Y)-15.85%0.28%
Total return CAGR (5Y)-57.15%-39.94%

Frequently asked

Which has grown faster, ALGS or ARAY?
Over the past five years, ARAY grew revenue faster — ALGS at a -15.85% CAGR versus ARAY at 0.28%.
How have ALGS and ARAY total returns compared?
Over the past 5 years, ALGS delivered -57.15% and ARAY delivered -39.94% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.